Meeting
2022 ASCO Genitourinary Cancers Symposium
Assessment of patient-reported outcomes (PROs) and longer-term adverse events (AEs) in phase I study of 225Ac-J591-PSMA for metastatic castration-resistant prostate cancer (mCRPC).
Authors
Jones T. Nauseef
New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY
Jones T. Nauseef , Charlene Thomas , Benedict Ho , Juana Martinez Zuloaga , Brian D. Gonzalez , Michael Sun , A. Oliver Sartor , Sharon Singh , Mahelia Bissassar , Escarleth Fernandez , Angela Tan , Amie Patel , Muhammad Obaid Naiz , Shankar Vallabhajosula , Ana M. Molina , Cora N. Sternberg , David M. Nanus , Joseph Osborne , Neil Harrison Bander , Scott T. Tagawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care
Clinical Trial Registration Number
NCT03276572
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 77)
DOI
10.1200/JCO.2022.40.6_suppl.077
Abstract #
77
Poster Bd #
D5
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Scott T. Tagawa
Poster
2024 ASCO Genitourinary Cancers Symposium
Patient reported outcomes (PROs) among patients with metastatic castration-resistant prostate cancer (mCRPC) by homologous recombination repair mutations (HRRm) gene clusters: Findings from the phase 3 TALAPRO-2 study cohort 2.
First Author: Karim Fizazi
Poster
2024 ASCO Genitourinary Cancers Symposium
Patient-reported outcomes (PROs) with talazoparib (TALA) plus enzalutamide (ENZA) vs. placebo (PBO) plus ENZA in men with metastatic castration-resistant prostate cancer (mCRPC): Subgroup analysis of patients with novel hormonal therapy (NHT) pretreatment in the TALAPRO-2 study.
First Author: Ugo De Giorgi
Poster
2023 ASCO Genitourinary Cancers Symposium
Patient-reported outcomes (PROs) in KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) vs abiraterone acetate (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC).
First Author: Niven Mehra